CJC‑1295 and ipamorelin are growth hormone (GH) secretagogues used together to stimulate endogenous GH release and increase downstream insulin‑like growth factor‑1 (IGF‑1). Unlike exogenous GH, secretagogues act through intact hypothalamic–pituitary pathways, preserving negative feedback and physiologic regulation of hormone secretion 1. Understanding how these agents work, including formulation differences of CJC‑1295, is essential for appropriate clinical use....